Mostrar el registro sencillo del ítem

Artículo

dc.creatorBerenguer, Juanes
dc.creatorBorobia, Alberto M.es
dc.creatorRyan, Pabloes
dc.creatorRodríguez-Baño, Jesúses
dc.creatorBellón, José M.es
dc.creatorJarrín, Inmaculadaes
dc.creatorCarratalà, Jordies
dc.creatorPachón Díaz, Jerónimoes
dc.creatorCarcas, Antonio J.es
dc.creatorYllescas, Maríaes
dc.creatorArribas, José Ramónes
dc.date.accessioned2022-10-06T10:55:57Z
dc.date.available2022-10-06T10:55:57Z
dc.date.issued2021
dc.identifier.citationBerenguer, J., Borobia, A.M., Ryan, P., Rodríguez-Baño, J., Bellón, J.M., Jarrín, I.,...,Arribas, J.R. (2021). Development and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC score. Thorax, 76 (9), 920-929. https://doi.org/doi:10.1136/thoraxjnl-2020-216001.
dc.identifier.issn0040-6376es
dc.identifier.issn1468-3296 (electrónico)es
dc.identifier.urihttps://hdl.handle.net/11441/137685
dc.description.abstractObjective: To develop and validate a prediction model of mortality in patients with COVID-19 attending hospital emergency rooms. Design Multivariable prognostic prediction model. Setting 127 Spanish hospitals. Participants Derivation (DC) and external validation (VC) cohorts were obtained from multicentre and single-centre databases, including 4035 and 2126 patients with confirmed COVID-19, respectively. Interventions Prognostic variables were identified using multivariable logistic regression. Main outcome measures 30-day mortality. Results: Patients’ characteristics in the DC and VC were median age 70 and 61 years, male sex 61.0% and 47.9%, median time from onset of symptoms to admission 5 and 8 days, and 30-day mortality 26.6% and 15.5%, respectively. Age, low age-adjusted saturation of oxygen, neutrophil-to-lymphocyte ratio, estimated glomerular filtration rate by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, dyspnoea and sex were the strongest predictors of mortality. Calibration and discrimination were satisfactory with an area under the receiver operating characteristic curve with a 95% CI for prediction of 30-day mortality of 0.822 (0.806–0.837) in the DC and 0.845 (0.819–0.870) in the VC. A simplified score system ranging from 0 to 30 to predict 30-day mortality was also developed. The risk was considered to be low with 0–2 points (0%–2.1%), moderate with 3–5 (4.7%–6.3%), high with 6–8 (10.6%–19.5%) and very high with 9–30 (27.7%–100%). Conclusions: A simple prediction score, based on readily available clinical and laboratory data, provides a useful tool to predict 30-day mortality probability with a high degree of accuracy among hospitalised patients with COVID-19.es
dc.description.sponsorshipFundación SEIMC/GeSIDAes
dc.description.sponsorshipPlan Nacional de I+D+i 2013-2016 and Instituto de Salud Carlos IIIes
dc.description.sponsorshipSubdirección General de Redes y Centros de Investigación Cooperativaes
dc.description.sponsorshipMinisterio de Ciencia, Innovación y Universidadeses
dc.description.sponsorshipEuropean Development Regional Fund “A way to achieve Europe”, Operative program Intelligent Growth 2014-2020es
dc.description.sponsorshipSpanish AIDS Research Network (RIS) (RD16/0025/0017 (JB), RD16/0025/0018 (JRA), RD16CIII/0002/0006 (IJ))es
dc.description.sponsorshipSpanish Network for Research in Infectious Diseases (REIPI) (RD16/0016/0001 (JRB), RD16/0016/0005 (JC) and RD16/0016/0009 (JP))es
dc.formatapplication/pdfes
dc.format.extent10 p.es
dc.language.isoenges
dc.publisherBMJ PUBLISHING GROUPes
dc.relation.ispartofThorax, 76 (9), 920-929.
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectClinical epidemiologyes
dc.subjectCritical carees
dc.subjectEmergency medicinees
dc.subjectPneumoniaes
dc.subjectRespiratory infectiones
dc.subjectViral infectiones
dc.titleDevelopment and validation of a prediction model for 30-day mortality in hospitalised patients with COVID-19: the COVID-19 SEIMC scorees
dc.typeinfo:eu-repo/semantics/articlees
dcterms.identifierhttps://ror.org/03yxnpp24
dc.type.versioninfo:eu-repo/semantics/publishedVersiones
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses
dc.relation.projectID(RIS) (RD16/0025/0017 (JB)es
dc.relation.projectIDRD16/0025/0018 (JRA)es
dc.relation.projectIDRD16CIII/0002/0006 (IJ))es
dc.relation.projectID(REIPI) (RD16/0016/0001 (JRB)es
dc.relation.projectIDRD16/0016/0005 (JC)es
dc.relation.projectIDRD16/0016/0009 (JP))es
dc.relation.publisherversionhttps://thorax.bmj.com/content/76/9/920es
dc.identifier.doidoi:10.1136/thoraxjnl-2020-216001es
dc.journaltitleThoraxes
dc.publication.volumen76es
dc.publication.issue9es
dc.publication.initialPage920es
dc.publication.endPage929es

FicherosTamañoFormatoVerDescripción
Development and validation of a ...949.5KbIcon   [PDF] Ver/Abrir  

Este registro aparece en las siguientes colecciones

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como: Attribution-NonCommercial-NoDerivatives 4.0 Internacional